RxDoctor Payments DataLook up a doctor →

Sarah Perlman

Family · Yakima, WANPI 1164704169

Payments from drug & device makers

$11,931in general payments, 2019–2025

Across 481 payments — averaging $24.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$2K
  • Lilly USA, LLC$972
  • Abbott$841
  • Bayer$742
  • Novo Nordisk$543
  • plus $5K from 34 others

What the payments were for

  • Food & beverage$11,80899%
  • Education$1231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,931 in reported general payments places this provider in the 95th percentile of 1,706 family providers in Washington.

See all family providers in Washington

Medicare billing

Part B allowed, 2024
$10,640
Medicare patients
63
Services billed
193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol53$59,757
OzempicSemaglutide35$54,133
JardianceEmpagliflozin34$41,854
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$40,538
TrulicityDulaglutide16$30,747
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$28,476
MounjaroTirzepatide12$22,106
EliquisApixaban14$21,551
Tresiba Flextouch U-200Insulin Degludec16$19,473
JanuviaSitagliptin Phosphate13$16,508
XareltoRivaroxaban12$14,979
VascepaIcosapent Ethyl11$6,840
Colesevelam Hcl13$4,584
Albuterol Sulfate HfaAlbuterol Sulfate109$4,285
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$3,962

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$1,855$88,23482 claims
Novo NordiskOzempic$543$54,13335 claims
Lilly USA, LLCTrulicity, Mounjaro$972$52,85328 claims
Boehringer IngelheimJardiance$370$41,85434 claims
GSKTrelegy Ellipta$285$40,53833 claims
PfizerEliquis$109$21,55114 claims
MerckJanuvia$185$16,50813 claims
Johnson & JohnsonXarelto$268$14,97912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,706 family providers in Washington.

Other family in Yakima

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →